Polygodial

Research use only, not for human use.

Polygodial is an antifungal potentiator and an antibiotic, particularly against Saccharomyces cerevisiae, Candida utilis, and Sclerotinia libertiana.

Polygodial is an antifungal potentiator and an antibiotic, particularly against Saccharomyces cerevisiae, Candida utilis, and Sclerotinia libertiana.(In Vitro):When tested on S. cerevisiae, polygodial proved to be fungicidal rather than fungistatic. When the cells of S. cerevisiae are treated in vitro with polygodial for 10 min, the cell membrane becomes severely damaged, and many vesicles, possibly formed from the fragmented cell membrane, can be observed within the cytoplasm.(In Vivo):Polygodial (0.1 to 10 mg kg(-1), i.p.) produced significant inhibition of acetic acid, kaolin and zymosan-induced writhing in mice, being about 14 to 27-fold more potent than the hydroalcoholic extract at the ID50 level.

Polygodial exhibits fungicidal activity against?Saccharomyces cerevisiae,?Candida albicans, and other fungal pathogens in standardized susceptibility tests (NCCLS). Polygodial (12.5 μg/mL, 3 hours) induces significant shrinkage compared to controls inSaccharomyces cerevisiae cells with the minimum fungicidal concentration (MFC) for 106?CFU/mL in RPMI 1640 medium. Cell Viability Assay Cell Line:S. cerevisiae cells Concentration:12.5 μg/mL Incubation Time:3 hours Result:Treated cells exhibited significant shrinkage compared to controls, and the organization of subcellular organelles appears either disrupted or compacted.

Polygodial is a sesquiterpene isolated from the barks of Drymis winteri (Winteraceae). Polygodial (0.5 to 10 mg/kg; 0.5 h; given by i.p. route to mice) induces significant, dose-related and almost complete inhibition of Acetic acid, Kaolin and Zymosan-induced abdominal constrictions. The calculated mean ID50 values are 0.8, 2.1 and 2.6 mg/kg and maximal inhibitions of 90.0±3.0, 98.0±1.0 and 97.0±2.0 %, against Acetic acid, Kaolin and Zymosan, respectively. Polygodial is about 14- to 27-fold more potent than the hydroalcoholic extract (HE) at the ID50 level. Animal Model:Non-fasted male Swiss mice (20-30 g) or male Wistar rats (150-180 g) Dosage:0.1 to 10 mg/kg Administration:Injected i.p. 0.5 h before the injection of irritant substances Result:Produced significant inhibition of Acetic acid, Kaolin and Zymosan-induced writhing in mice.

Tadeonal

GPCR/G Protein

Antibacterial

TNF-α

——

——

6754-20-7

234.339

C15H22O2

>98% (HPLC)

In Vitro:?DMSO : ≥ 100 mg/mL (426.75 mM)

[H][C@@]12CC=C(C=O)[C@H](C=O)[C@@]1(C)CCCC2(C)C

——

(-20℃)

With Ice Pack

≥ 2 years